General Biotechnology

General Biotechnology

Using Biotechnology, CSI, and Zombies to Promote Science Education in one of America’s Most Challenging Regions

This paper examines the creation of a forensic biotechnology program that engages students, promotes science learning beyond the classroom and makes available novel STEM opportunities to an area which previously had little biotechnology educational off…

Using Biotechnology, CSI, and Zombies to Promote Science Education in one of America’s Most Challenging Regions Read Post »

General Biotechnology

Biogenerics 2007: How far have we come?

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Biogenerics 2007: How far have we come?

Go to paper

ABSTRACT: The recent approval of a follow-on version of Pfizer’s Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection. This paper describes many of the key scientific challenges facing the nascent ‘biogenerics’ industry and the evolving regulatory framework that will shape its competition with innovator companies…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Biogenerics 2007: How far have we come? Read Post »

General Biotechnology

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad

Go to paper

ABSTRACT: This paper analyses the recent ruling in Kinik Co. v. Int’l Trade Comm’n, 362 F.3d 1359 (Fed. Cir. 2004), and the impact that decision may have on proceedings before the US International Trade Commission under the Tariff Act of 1930 (19 USC §1337(a)) – particularly those concerning the importation of products derived from practising US patented processes abroad.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Kinik: Raising the stakes for importing products derived from US patented processes practised abroad Read Post »

Biotechblog
Scroll to Top